慢性乙型肝炎合并非酒精性脂肪性肝病的临床研究进展

曹丹; 陈文静; 李艳平; 陈延平

doi:10.3969/j.issn.1001-5256.2018.09.033

慢性乙型肝炎合并非酒精性脂肪性肝病的临床研究进展

DOI: 10.3969/j.issn.1001-5256.2018.09.033

延安大学附属医院感染病科

基金项目:

陕西省重点研发计划项目(2017SF-269)；延安市科技创新团队建设项目(2017C×TD-02)；

详细信息

中图分类号: R575.5;R512.62
计量
- 文章访问数: 2165
- HTML全文浏览量: 28
- PDF下载量: 446
- 被引次数: 0
出版历程
- 收稿日期: 2018-03-22
- 出版日期: 2018-09-20

Research advances in chronic hepatitis B complicated by nonalcoholic fatty liver disease

Department of Infectious Diseases, Yan'an University Affiliated Hospital

Research funding:

摘要

摘要: 非酒精性脂肪性肝病(NAFLD)已成为全球第一大慢性肝病,慢性乙型肝炎(CHB)合并NAFLD也越来越常见,逐渐受到临床医师的重视。目前对CHB合并NAFLD的临床特征及预后尚未形成明确认识。通过对CHB合并NAFLD相关文献的归纳,综述了该病发生的危险因素和生化学、病毒学、组织学以及预后等方面的临床研究进展。认为年龄、男性及代谢紊乱是CHB患者发生NAFLD的危险因素;CHB合并NAFLD患者肝硬化及肝细胞癌的发生风险增加。但目前关于NAFLD对CHB患者病毒复制及清除的影响及其机制、HBV感染对NAFLD发生的影响尚不清楚,这将成为今后的研究热点。
- 肝炎,乙型,慢性 /
- 非酒精性脂肪性肝病 /
- 综述
Abstract: Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease around the world, and chronic hepatitis B (CHB) complicated by NAFLD has also become more and more common and is taken seriously by clinical physicians. At present, there is no clear understanding of the clinical features and prognosis of CHB complicated by NAFLD. With reference to related literature on CHB complicated by NAFLD, this article reviews the research advances in the risk factors, biochemistry, virology, histology, and prognosis of CHB complicated by NAFLD. It is pointed out that age, male sex, and metabolic disorders are the risk factors for NAFLD in CHB patients, and patients with CHB complicated by NAFLD have a high risk of liver cirrhosis and hepatocellular carcinoma. However, the effect and mechanism of NAFLD on virus replication and clearance in CHB patients and the effect of HBV infection on the development of NAFLD remain unclear, which will be research hotspots in future.
- hepatitis B, chronic /
- non-alcoholic fatty liver disease /
- review

HTML全文

参考文献(36)

[1]YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J].Hepatology, 2016, 64 (1) :73-84.

[2]FAN JG, KIM SU, WONG VW.New trends on obesity and NAFLDin Asia[J].J Hepatol, 2017, 67 (4) :862-873.

[3]MACHADO MV, OLIVEIRA AG, CORTEZ-PINTO H.Hepatic steatosis in hepatitis B virus infected patients:Meta-analysis of risk factors and comparison with hepatitis C infected patients[J].JGastroenterol Hepatol, 2011, 26 (9) :1361-1367.

[4]WANG MM, WANG GS, SHEN F, et al.Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors[J].Dig Dis Sci, 2014, 59 (10) :2571-2579.

[5]PENG D, HAN Y, DING H, et al.Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors[J].J Gastroenterol Hepatol, 2008, 23 (7 Pt 1) :1082-1088.

[6]CHU CM, LIN DY, LIAW YF.Clinical and virological characteristics post HBs Ag seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without[J].Dig Dis Sci, 2013, 58 (1) :275-281.

[7]HUI RWH, SETO WK, CHEUNG KS, et al.Inverse relationship between hepatic steatosis and hepatitis B viremia:Results of a large case-control study[J].J Viral Hepat, 2018, 25 (1) :97-104.

[8]SHI JP, FAN JG, WU R, et al.Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection[J].J Gastroenterol Hepatol, 2008, 23 (9) :1419-1425.

[9]JIN X, CHEN YP, YANG YD, et al.Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B[J].PLo S One, 2012, 7 (3) :e34198.

[10]ZHANG ZQ, WANG GS, KANG KF, et al.Prevalence and clinical features of hepatic steatosis in patients with chronic hepatitis B[J].J Clin Hepatol, 2015, 31 (7) :1063-1067. (in Chinese) 张志侨, 王功遂, 康凯夫, 等.慢性乙型肝炎合并非酒精性脂肪性肝病的临床特征分析[J].临床肝胆病杂志, 2015, 31 (7) :1063-1067.

[11]PAN Q, ZHANG RN, WANG YQ, et al.Linked PNPLA3 polymorphisms confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B[J].World J Gastroenterol, 2015, 21 (28) :8605-8614.

[12]ROMEO S, KOZLITINA J, XING C, et al.Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J].Nat Genet, 2008, 40 (12) :1461-1465.

[13]ESLAM M, MANGIA A, BERG T, et al.Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes[J].Hepatology, 2016, 64 (1) :34-46.

[14]WONG VW, WONG GL, TSE CH, et al.Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese[J].J Hepatol, 2014, 61 (3) :708-709.

[15]ZHONG GC, WU YL, HAO FB, et al.Current but not past hepatitis B virus infection is associated with a decreased risk of nonalcoholic fatty liver disease in the Chinese population:A case-control study with propensity score analysis[J].J Viral Hepat, 2018, 25 (7) :842-852.

[16]JOO EJ, CHANG Y, YEOM JS, et al.Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease:A cohort study[J].Hepatology, 2017, 65 (3) :828-835.

[17]ENOMOTO H, AIZAWA N, NISHIKAWA H, et al.Relationship between hepatic steatosis and the elevation of aminotransferases in HBV-infected patients with HBe-antigen negativity and a low viral load[J].Medicine (Baltimore) , 2016, 95 (17) :e3565.

[18]LIN CW, HUANG XL, LIU HL, et al.Interactions of hepatitis Bvirus infection with nonalcoholic fatty liver disease:Possible mechanisms and clinical impact[J].Dig Dis Sci, 2015, 60 (12) :3513-3524.

[19]LIU SF, WU BR, LIU ZZ, et al.Clinic characteristics of patients with chronic hepatitis B overlapped with non-alcoholic fatty liver diseases[J].J Pract Hepatol, 2015, 18 (5) :540-541. (in Chinese) 刘素芬, 武博荣, 刘振中, 等.非酒精性脂肪性肝病合并HBV感染患者临床特征分析[J].实用肝脏病杂志, 2015, 18 (5) :540-541.

[20]CHEN Y, FAN C, CHEN Y, et al.Effect of hepatic steatosis on the progression of chronic hepatitis B:A prospective cohort and in vitro study[J].Oncotarget, 2017, 8 (35) :58601-58610.

[21]LIANG J, CAI W, HAN T, et al.The expression of thymosinβ4 in chronic hepatitis B combined nonalcoholic fatty liver disease[J].Medicine (Baltimore) , 2016, 95 (52) :e5763.

[22]YANG XZ, GENG AW, XIAO L, et al.Pathological and clinical features of patients with chronic hepatitis B and non-alcoholic fatty liver disease[J].J Pract Hepatol, 2017, 20 (1) :101-102. (in Chinese) 杨秀珍, 耿爱文, 肖丽, 等.慢性乙型肝炎合并脂肪肝临床与肝组织病理学分析[J].实用肝脏病杂志, 2017, 20 (1) :101-102.

[23]CEYLAN B, ARSLAN F, BATIREL A, et al.Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir[J].Turk J Gastroenterol, 2016, 27 (1) :42-46.

[24]KARACAER Z.Non-alcoholic fatty liver disease in chronic hepatitis B patients[J].Turk J Gastroenterol, 2016, 27 (4) :395-396.

[25]ZHANG ZQ, WANG GS, KANG KF, et al.The clinical and pathological features of hepatic steatosis in patients with chronic hepatitis B based on a matched case-control study[J].Chin J Infect Dis, 2016, 34 (3) :146-150. (in Chinese) 张志侨, 王功遂, 康凯夫, 等.基于216对配对病例研究慢性乙型肝炎患者肝脂肪变性的临床和病理特征[J].中华传染病杂志, 2016, 34 (3) :146-150.

[26]CHEN JN, ZHUANG QY, CHEN BF, et al.The influencing factors of hepatic steatosis in patients with chronic hepatitis B[J].Chin J Infect Dis, 2013, 31 (3) :160-165. (in Chinese) 陈建能, 庄群瑛, 陈碧芬, 等.慢性乙型肝炎合并肝脂肪变的影响因素[J].中华传染病杂志, 2013, 31 (3) :160-165.

[27]ZHU Y, YANG Q, LV F, et al.The effect of hepatosteatosis on response to antiviral treatment in patients with chronic hepatitis B:Ameta-analysis[J].Gastroenterol Res Pract, 2017, 2017:1096406.

[28]CHEN J, WANG ML, LONG Q, et al.High value of controlled attenuation parameter predicts a poor antiviral response in patients with chronic hepatits B[J].Hepatobiliary Pancreat Dis Int, 2017, 16 (4) :370-374.

[29]WU YQ, SHEN LJ, YU JH, et al.Clinical effect of entecavir in treatment of chronic hepatitis B complicated by hepatic steatosis[J].J Clin Hepatol, 2017, 33 (5) :849-852. (in Chinese) 吴艳琴, 沈黎俊, 于集虹, 等.恩替卡韦治疗慢性乙型肝炎合并肝脂肪变的效果评价[J].临床肝胆病杂志, 2017, 33 (5) :849-852.

[30]GONG L, LIU J, WANG J, et al.Hepatic steatosis as a predictive factor of antiviral effect of pegylated interferon therapy in patients with hepatitis B[J].Transplant Proc, 2015, 47 (10) :2886-2891.

[31]ZHU LY, ZHOU J, FENG WG, et al.The comparison of the efficacy of entecavir in the treatment of patients with chronic hepatitis Band non-alcoholic fatty liver disease[J].Chin J Infect Dis, 2016, 34 (6) :362-363. (in Chinese) 朱礼尧, 周建, 冯伟广, 等.恩替卡韦治疗单纯慢性乙型肝炎和合并非酒精性脂肪性肝病患者的效果比较[J].中华传染病杂志, 2016, 34 (6) :362-363.

[32]MI YQ, LIU YG, XU L, et al.The association between hepatic steatosis and HBs Ag and HBc Ag in chronic hepatitis B patients[J].Chin J Dig, 2012, 32 (5) :316-319. (in Chinese) 宓余强, 刘勇钢, 徐亮, 等.慢性乙型肝炎患者肝脂肪变与肝脏HBs Ag和HBc Ag的关系[J].中华消化杂志, 2012, 32 (5) :316-319.

[33]KARACAER Z, OKUR G, CERMIK H, et al.Is there an influence of hepatic steatosis on fibrosis and necroinflammation in young patients with chronic viral hepatitis B[J].Postgrad Med, 2016, 128 (7) :697-700.

[34]SETO WK, HUI RWH, MAK LY, et al.Association between hepatic steatosis, measured by controlled attenuation parameter, and fibrosis burden in chronic hepatitis B[J].Clin Gastroenterol Hepatol, 2018, 16 (4) :575-583.

[35]FAN JG, CHEN GF, JI D, et al.Long-term disease progression in chronic hepatitis B Chinese patients with comorbid nonalcoholic fatty liver disease[J].J Hepatol, 2017, 66 (1) :s416-s417.

[36]CHAN AW, WONG GL, CHAN HY, et al.Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B[J].J Gastroenterol Hepatol, 2017, 32 (3) :667-676.

施引文献

资源附件(0)

访问统计